Une poster présenté lors de la conférence #EACS2023 détaillait l'utilisation de la PrEP par 161 femmes fréquentant une clinique à Paris entre avril 2017 et avril 2023. Il a révélé que la majorité des utilisatrices de PrEP étaient des personnes trans (60 % du total).
Italian study suggests simple BMI is as reliable as more complex tests in predicting diabetes for people with HIV.
An aidsmap report from #EACS2023.
www.aidsmap.com/news/oct-202...
Malheureusement, la stratégie de double allégement thérapeutique (une bitherapie VIH en comprimés 4 jours par semaine) c’est pas pour tout de suite. L’essai Duetto a été interrompu il y a quelques mois.
#EACS2023
People with HIV are changing their treatment regimen twice as often as a decade ago.
New data from London presented at #EACS2023 👇
www.aidsmap.com/news/oct-202...
News from #IDWeek2023 & #EACS2023: #HIV+ people treated with trichloroacetic acid were about as likely to experience improvement of precancerous anal cell lesions as those who underwent electrocautery, but were less likely to experience side effects. 1/
High frequency of PTSD observed among people with HIV at Amsterdam clinic - with symptoms more likely among younger rather than older people.
An aidsmap report from #EACS2023.
www.aidsmap.com/news/oct-202...
COVID increased the risk of a major cardiovascular event for people with HIV by 35%.
An aidsmap report from #EACS2023.
www.aidsmap.com/news/oct-202...
The majority of gay and bi migrant men in France with #HIV acquired it *after* moving to France - and were more likely to acquire HIV in the first years after arrival.
An aidsmap report from #EACS2023.
www.aidsmap.com/news/oct-202...
I'm taking time out from #EACS2023 & #ESMO2023 for this PolyBio symposium on longCOVID & MECFS. And it's not unrelated. Long-term sequelae after viral infection is a fascinating area that could lead to better understanding of immune response, with implications for #HIV cure & cancer therapies.
La moitié des prescriptions de PrEP en Europe sont faites au Royaume-Uni et en France. Mais pas de quoi fanfaronner car même chez nous, la PrEP est loin d'atteindre toutes les populations les plus exposées au VIH (notamment les femmes migrantes).
#EACS2023
News from #IDWeek2023 & #EACS2023: Sunlenca (lenacapavir) remains active at 2 years in people with resistant #HIV, mostly mild to moderate injection site reactions, proportion with CD4 count <200 fell from 64% at baseline to 29%.